JP6767483B2 - 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター - Google Patents

遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター Download PDF

Info

Publication number
JP6767483B2
JP6767483B2 JP2018521395A JP2018521395A JP6767483B2 JP 6767483 B2 JP6767483 B2 JP 6767483B2 JP 2018521395 A JP2018521395 A JP 2018521395A JP 2018521395 A JP2018521395 A JP 2018521395A JP 6767483 B2 JP6767483 B2 JP 6767483B2
Authority
JP
Japan
Prior art keywords
nucleic acid
fxn
seq
sequence
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018521395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531609A5 (enExample
JP2018531609A (ja
Inventor
ジェイ． サムルスキー リチャード
ジェイ． サムルスキー リチャード
Original Assignee
バンブー セラペウティクス インク
バンブー セラペウティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バンブー セラペウティクス インク, バンブー セラペウティクス インク filed Critical バンブー セラペウティクス インク
Publication of JP2018531609A publication Critical patent/JP2018531609A/ja
Publication of JP2018531609A5 publication Critical patent/JP2018531609A5/ja
Application granted granted Critical
Publication of JP6767483B2 publication Critical patent/JP6767483B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
JP2018521395A 2015-11-05 2016-11-01 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター Expired - Fee Related JP6767483B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562251288P 2015-11-05 2015-11-05
US62/251,288 2015-11-05
US201662411980P 2016-10-24 2016-10-24
US62/411,980 2016-10-24
PCT/IB2016/056572 WO2017077451A1 (en) 2015-11-05 2016-11-01 Modified friedreich ataxia genes and vectors for gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156320A Division JP2021019591A (ja) 2015-11-05 2020-09-17 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター

Publications (3)

Publication Number Publication Date
JP2018531609A JP2018531609A (ja) 2018-11-01
JP2018531609A5 JP2018531609A5 (enExample) 2019-12-12
JP6767483B2 true JP6767483B2 (ja) 2020-10-14

Family

ID=57288476

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521395A Expired - Fee Related JP6767483B2 (ja) 2015-11-05 2016-11-01 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
JP2020156320A Pending JP2021019591A (ja) 2015-11-05 2020-09-17 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020156320A Pending JP2021019591A (ja) 2015-11-05 2020-09-17 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター

Country Status (18)

Country Link
US (2) US10548947B2 (enExample)
EP (1) EP3370778A1 (enExample)
JP (2) JP6767483B2 (enExample)
KR (2) KR102200642B1 (enExample)
CN (1) CN108348621A (enExample)
AU (2) AU2016347887B2 (enExample)
BR (1) BR112018007453A2 (enExample)
CA (1) CA2947584A1 (enExample)
CO (1) CO2018004564A2 (enExample)
HK (1) HK1250924A1 (enExample)
IL (1) IL259141A (enExample)
MX (1) MX2018005084A (enExample)
PE (1) PE20181156A1 (enExample)
PH (1) PH12018500964A1 (enExample)
RU (2) RU2021102893A (enExample)
SG (2) SG11201802408RA (enExample)
TW (2) TWI654301B (enExample)
WO (1) WO2017077451A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021019591A (ja) * 2015-11-05 2021-02-18 バンブー セラペウティクス インク 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3286321A4 (en) * 2015-04-24 2018-10-17 University of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
JP6745873B2 (ja) 2015-05-22 2020-08-26 ドミトリエヴィッチ ゲンキン，ドミトリー 神経変性における治療標的としての細胞外ｄｎａ
US12011488B2 (en) 2016-03-23 2024-06-18 The Regents Of The University Of California Methods of treating mitochondrial disorders
AU2017237912B2 (en) 2016-03-23 2022-03-10 The Regents Of The University Of California Methods of treating mitochondrial disorders
WO2018057615A1 (en) 2016-09-21 2018-03-29 Commscope Technologies Llc Adapter block assembly
CA3042706A1 (en) * 2016-11-09 2018-05-17 Intrexon Corporation Frataxin expression constructs
EP3687582A4 (en) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
CN112501208A (zh) 2017-10-03 2021-03-16 普利维尔治疗公司 用于溶酶体障碍的基因疗法
US11802294B2 (en) * 2017-10-03 2023-10-31 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
BR112020006661A2 (pt) 2017-10-03 2020-10-13 Prevail Therapeutics, Inc. terapias de genes para distúrbios lipossomais
PL3697914T3 (pl) * 2017-10-17 2023-10-16 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Wektory do leczenia ataksji friedreicha
JP2021510539A (ja) 2018-01-16 2021-04-30 シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置
WO2019195449A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
EP3773743A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
CN112543766A (zh) 2018-04-03 2021-03-23 斯特里迪比奥公司 抗体逃避性病毒载体
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
KR20210086601A (ko) * 2018-08-02 2021-07-08 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
CA3109114A1 (en) * 2018-08-10 2020-02-13 Logicbio Therapeutics, Inc. Non-disruptive gene therapy for the treatment of methaylmalonic aciduria
SG11202103151RA (en) * 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
EP3880179A2 (en) * 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
WO2020102645A1 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease
EA202191418A1 (ru) * 2018-11-21 2021-08-05 Страйдбайо, Инк. Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения
KR20210117271A (ko) * 2018-12-21 2021-09-28 노쓰웨스턴유니버시티 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
AU2020248101A1 (en) * 2019-03-27 2021-09-16 Sigilon Therapeutics, Inc. Compositions, devices and methods for factor VII therapy
BR112021019224A2 (pt) * 2019-03-28 2021-11-30 Intellia Therapeutics Inc Polinucleotídeos, composições e métodos para expressão de polipeptídeo
WO2020210713A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
EP3989994A4 (en) * 2019-06-30 2023-08-09 John Fraser Wright RECOMBINANT AAV VECTORS WITH ALTERED IMMUNOGENICITY AND METHODS FOR THEIR PRODUCTION
EP3999120A4 (en) * 2019-07-04 2024-02-21 Children's Medical Research Institute Methods and aav vectors for in vivo transduction
US20220241394A1 (en) * 2019-07-12 2022-08-04 Cls Therapeutics Limited TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY
CA3151073A1 (en) * 2019-09-13 2021-03-18 Darin Falk Compositions and methods for treatment of friedreich's ataxia
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療ｃ型尼曼—匹克病之腺相關病毒載體
AU2020405149A1 (en) * 2019-12-19 2022-07-07 The Trustees Of The University Of Pennsylvania Compositions for treating Friedreich's ataxia
CN113755524B (zh) * 2020-06-02 2023-11-03 舒泰神（北京）生物制药股份有限公司 用于治疗脊髓性肌萎缩的腺相关病毒载体及其用途
US11946065B2 (en) 2020-07-29 2024-04-02 The Board Of Regents Of The University Of Texas System Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB
TW202227632A (zh) 2020-08-19 2022-07-16 美商史崔德生物公司 用於治療雷特症候群之腺相關病毒載體
IL302608A (en) 2020-11-03 2023-07-01 Pfizer Methods for purification of aav vectors by anion exchange chromatography
IL303959A (en) 2020-12-23 2023-08-01 Pfizer Methods for purification of aav vectors by affinity chromatography
CA3207161A1 (en) * 2021-01-04 2022-07-07 University Of Florida Research Foundation, Incorporated Methods and compositions for treatment of friedreich's ataxia
US20240050521A1 (en) * 2021-01-11 2024-02-15 The Trustees Of The University Of Pennsylvania Compositions for treating friedreich's ataxia
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2024003687A1 (en) 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
CA3257440A1 (en) * 2022-07-06 2024-01-11 Adverum Biotechnologies Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACHROMOTOPSY
CN117089514A (zh) * 2023-10-13 2023-11-21 思鹏生物科技(苏州)有限公司 提升hek293细胞系aav生产效率的细胞筛选驯化方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
AU707862B2 (en) 1995-06-07 1999-07-22 University Of North Carolina At Chapel Hill, The Helper virus-free aav production
ATE465267T1 (de) 1996-09-06 2010-05-15 Univ Pennsylvania Rekombinante aav zur herstellung eines medikaments für die gentherapie von muskelzellen
EP0932694A2 (en) 1996-09-11 1999-08-04 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ES2313784T3 (es) 1998-05-28 2009-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Vector aav5 y usos del mismo.
ATE362542T1 (de) 1998-11-05 2007-06-15 Univ Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
CA2399576A1 (en) 2000-12-07 2002-06-13 Universite De Nantes Inducible highly productive raav packaging cell-lines
EP2298926A1 (en) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
CA2591544A1 (en) 2004-12-15 2006-06-22 The University Of North Carolina At Chapel Hill Chimeric vectors
US9163249B2 (en) * 2007-08-20 2015-10-20 Glaxo Group Limited Production methods
ES2634118T3 (es) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
WO2011084145A2 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
WO2011097640A1 (en) * 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
EP2718439B1 (en) * 2011-06-09 2017-08-09 CuRNA, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
JP6165752B2 (ja) 2011-10-28 2017-07-19 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル アデノ随伴ウイルスの産生のための細胞株
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
EP2970943A4 (en) 2013-03-15 2017-04-19 The Children's Hospital of Philadelphia Vectors comprising stuffer/filler polynucleotide sequences and methods of use
CA2904396A1 (en) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav vectors
ES2897508T3 (es) 2013-05-31 2022-03-01 Univ California Variantes de virus adenoasociados y métodos de uso de las mismas
RU2705249C2 (ru) 2013-07-12 2019-11-06 Дзе Чилдрен'З Хоспитал Оф Филадельфия Вектор aav и анализ на нейтрализующие антитела против aav (аденоассоциированного вируса)
HUE047996T2 (hu) 2013-07-22 2020-05-28 Childrens Hospital Philadelphia AAV variáns és készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
JP6552511B2 (ja) 2013-10-11 2019-07-31 マサチューセッツ アイ アンド イヤー インファーマリー 祖先ウイルス配列を予測する方法およびその使用
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
CN108348621A (zh) * 2015-11-05 2018-07-31 竹治疗股份有限公司 用于基因治疗的经修饰的弗里德赖希共济失调基因及载体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021019591A (ja) * 2015-11-05 2021-02-18 バンブー セラペウティクス インク 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター

Also Published As

Publication number Publication date
KR102200642B1 (ko) 2021-01-12
AU2020200976A1 (en) 2020-02-27
BR112018007453A2 (pt) 2018-10-23
CN108348621A (zh) 2018-07-31
MX2018005084A (es) 2019-05-16
PH12018500964A1 (en) 2018-11-12
RU2018116076A3 (enExample) 2020-08-21
US20200384073A1 (en) 2020-12-10
KR20210005994A (ko) 2021-01-15
JP2021019591A (ja) 2021-02-18
RU2018116076A (ru) 2019-10-28
EP3370778A1 (en) 2018-09-12
PE20181156A1 (es) 2018-07-19
IL259141A (en) 2018-06-28
AU2016347887A1 (en) 2018-04-19
US20170128528A1 (en) 2017-05-11
AU2020200976B2 (en) 2021-09-30
TWI654301B (zh) 2019-03-21
TWI743442B (zh) 2021-10-21
TW201920673A (zh) 2019-06-01
KR20180077275A (ko) 2018-07-06
RU2021102893A (ru) 2021-03-03
WO2017077451A1 (en) 2017-05-11
SG10201912763QA (en) 2020-02-27
CA2947584A1 (en) 2017-05-05
HK1250924A1 (zh) 2019-01-18
RU2743792C2 (ru) 2021-02-26
SG11201802408RA (en) 2018-05-30
CO2018004564A2 (es) 2018-12-14
TW201723179A (zh) 2017-07-01
JP2018531609A (ja) 2018-11-01
US10548947B2 (en) 2020-02-04
AU2016347887B2 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
JP6767483B2 (ja) 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
JP6793758B2 (ja) 最適化されたミニ−ジストロフィン遺伝子および発現カセットおよびそれらの使用
KR102526616B1 (ko) 윌슨병 및 기타 병태의 치료에 사용되기 위한 핵산 구조물 및 유전자 치료용 벡터
KR20180091863A (ko) 임상적 사용에 적합한 무혈청 현탁 세포 배양 시스템에서 재조합 아데노-관련 바이러스(aav) 벡터를 생성하기 위한 확장가능한 방법
KR20160026841A (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
WO2015124546A1 (en) Aav vectors for the treatment of ischemic and non-ischemic heart disease
US20240091383A1 (en) Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy
US20220389456A1 (en) Modified soluble vegf receptor-1 genes and vectors for gene therapy
EP3262065B1 (en) Methods and compositions for treating dystroglycanopathy disorders
EP4159863A1 (en) Codon-optimized nucleic acid encoding smn1 protein
JP2025539750A (ja) 前頭側頭型認知症の遺伝子治療
CN112011571A (zh) 一种用于治疗脊髓性肌萎缩的基因治疗药物
US20230338582A1 (en) Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy
WO2023131345A1 (zh) 用于x染色体连锁肾上腺脑白质营养不良的基因治疗药物和方法
CN116179605B (zh) 一种重组腺相关病毒载体及其应用
RU2825667C2 (ru) Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 9 серотипа (AAV9), капсид и вектор на его основе
EP4198134A1 (en) Gamma-sarcoglycan gene transfer increase using modified itr sequences
WO2025217117A1 (en) Compositions with cardiac and skeletal muscle-specific targeting motifs and uses thereof
WO2023111102A1 (en) Alpha-sarcoglycan gene transfer increase using modified itr sequences
CN118696126A (zh) 用于治疗雷特综合征及相关病症的重组优化的mecp2盒和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191030

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191108

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200917

R150 Certificate of patent or registration of utility model

Ref document number: 6767483

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees